Molecular profiles of small cell lung cancer subtypes: therapeutic implications.
heterogeneity
molecular profile
neuroendocrine
small cell lung cancer
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
26 Mar 2021
26 Mar 2021
Historique:
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
epublish
Résumé
Small cell lung cancer (SCLC; accounting for approximately 13%-15% of all lung cancers) is an exceptionally lethal malignancy characterized by rapid doubling time and high propensity to metastasize. In contrast to the increasingly personalized therapies in other types of lung cancer, SCLC is still regarded as a homogeneous disease and the prognosis of SCLC patients remains poor. Recently, however, substantial progress has been made in our understanding of SCLC biology. Advances in genomics and development of new preclinical models have facilitated insights into the intratumoral heterogeneity and specific genetic alterations of this disease. This worldwide resurgence of studies on SCLC has ultimately led to the development of novel subtype-specific classifications primarily based on the neuroendocrine features and distinct molecular profiles of SCLC. Importantly, these biologically distinct subtypes might define unique therapeutic vulnerabilities. Herein, we summarize the current knowledge on the molecular profiles of SCLC subtypes with a focus on their potential clinical implications.
Identifiants
pubmed: 33718595
doi: 10.1016/j.omto.2021.02.004
pii: S2372-7705(21)00022-X
pmc: PMC7917449
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
470-483Subventions
Organisme : Austrian Science Fund FWF
ID : I 3522
Pays : Austria
Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
J Clin Oncol. 2020 Jul 20;38(21):2369-2379
pubmed: 32468956
Ann Transl Med. 2018 Apr;6(8):145
pubmed: 29862234
Radiographics. 2014 Oct;34(6):1707-21
pubmed: 25310425
Cancer. 2010 Mar 1;116(5):1350-7
pubmed: 20082453
Cancer Cell. 2014 Mar 17;25(3):318-34
pubmed: 24651013
Cancer Sci. 2016 Dec;107(12):1755-1766
pubmed: 27627196
Immunol Rev. 2008 Apr;222:206-21
pubmed: 18364004
Int J Cancer. 2018 Nov 1;143(9):2133-2144
pubmed: 29696628
N Engl J Med. 1999 Aug 12;341(7):476-84
pubmed: 10441603
Cancer Discov. 2018 Nov;8(11):1422-1437
pubmed: 30181244
J Clin Oncol. 1999 Nov;17(11):3540-5
pubmed: 10550152
Lancet. 2016 Mar 5;387(10022):968-977
pubmed: 26703889
Lancet Oncol. 2016 Jul;17(7):883-895
pubmed: 27269741
J Biol Chem. 2008 Jul 25;283(30):21160-9
pubmed: 18339630
Cell. 2016 Jul 14;166(2):328-342
pubmed: 27374332
Cold Spring Harb Perspect Med. 2020 Jun 8;:
pubmed: 32513672
Cancer Discov. 2012 Sep;2(9):798-811
pubmed: 22961666
Front Immunol. 2018 Jan 31;9:151
pubmed: 29445380
Clin Lung Cancer. 2011 Mar;12(2):87-93
pubmed: 21550554
J Clin Oncol. 2012 May 10;30(14):1692-8
pubmed: 22473169
J Clin Oncol. 2019 Jan 20;37(3):222-229
pubmed: 30523756
J Clin Oncol. 1985 Jan;3(1):65-71
pubmed: 2981293
J Clin Oncol. 2017 Dec 1;35(34):3823-3829
pubmed: 28813164
J Clin Oncol. 2007 May 20;25(15):2086-92
pubmed: 17513814
Curr Pharm Des. 2009;15(11):1191-202
pubmed: 19355960
Ther Clin Risk Manag. 2018 Jun 05;14:1019-1040
pubmed: 29892196
J Thorac Oncol. 2009 Sep;4(9):1049-59
pubmed: 19652623
JAMA. 1976 Mar 22;235(12):1225-9
pubmed: 55504
Cancer Discov. 2018 Oct;8(10):1316-1331
pubmed: 30228179
J Thorac Oncol. 2020 Mar;15(3):426-435
pubmed: 31629915
J Natl Cancer Inst. 2004 Jan 7;96(1):56-67
pubmed: 14709739
Cell Rep. 2016 Aug 2;16(5):1259-1272
pubmed: 27452466
Cancer Cell. 2017 Feb 13;31(2):270-285
pubmed: 28089889
Nature. 1997 Apr 24;386(6627):852-5
pubmed: 9126746
ESMO Open. 2018 Apr 27;3(3):e000366
pubmed: 29719730
Nat Genet. 2012 Oct;44(10):1111-6
pubmed: 22941189
Cancer Res. 2017 Sep 1;77(17):4652-4662
pubmed: 28667074
Oncotarget. 2017 Jun 28;8(54):93149-93155
pubmed: 29190984
Lung Cancer. 2003 Aug;41 Suppl 1:S49-53
pubmed: 12867062
Development. 2017 Mar 1;144(5):755-766
pubmed: 28246210
Biochem Biophys Res Commun. 2017 Sep 16;491(2):493-499
pubmed: 28684311
J Clin Oncol. 2018 Aug 10;36(23):2386-2394
pubmed: 29906251
Mod Pathol. 2014 Feb;27(2):214-21
pubmed: 23887299
Transl Lung Cancer Res. 2016 Feb;5(1):2-15
pubmed: 26958489
J Thorac Oncol. 2014 Aug;9(8):1140-5
pubmed: 25157766
J Thorac Oncol. 2018 Sep;13(9):1393-1399
pubmed: 29775808
Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S341-S345
pubmed: 30705850
J Oncol Pract. 2018 Jun;14(6):359-366
pubmed: 29894664
J Clin Oncol. 2011 Jun 1;29(16):2215-22
pubmed: 21502556
J Thorac Oncol. 2015 Feb;10(2):316-23
pubmed: 25319182
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Oncol Lett. 2012 Oct;4(4):617-620
pubmed: 23205072
Cancer Res. 1987 Oct 1;47(19):5009-13
pubmed: 3040237
J Hematol Oncol. 2019 Apr 25;12(1):45
pubmed: 31023335
J Thorac Oncol. 2020 Feb;15(2):274-287
pubmed: 31655296
Transl Lung Cancer Res. 2018 Feb;7(1):32-49
pubmed: 29535911
Cancer Res. 1985 Jun;45(6):2924-30
pubmed: 2985258
BMC Cancer. 2004 Oct 07;4:73
pubmed: 15471548
Science. 2016 Nov 4;354(6312):618-622
pubmed: 27811275
Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17034-9
pubmed: 23035247
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Front Immunol. 2019 Sep 26;10:2254
pubmed: 31616428
Gen Thorac Cardiovasc Surg. 2012 Jul;60(7):401-5
pubmed: 22638740
Oncologist. 2016 Oct;21(10):1163-1164
pubmed: 27694157
Nat Cancer. 2020 Apr;1:423-436
pubmed: 33521652
ESMO Open. 2019 Jun 12;4(Suppl 3):e000497
pubmed: 31275616
Curr Opin Oncol. 2020 Mar;32(2):106-113
pubmed: 31876547
Cancers (Basel). 2019 May 17;11(5):
pubmed: 31108964
Front Oncol. 2020 May 20;10:741
pubmed: 32509576
Eur J Cancer. 2015 Feb;51(3):421-6
pubmed: 25582496
J Thorac Dis. 2018 Aug;10(8):4689-4693
pubmed: 30233840
Nat Rev Cancer. 2019 May;19(5):289-297
pubmed: 30926931
Front Immunol. 2019 Jul 03;10:1505
pubmed: 31333652
Transl Lung Cancer Res. 2019 Dec;8(6):938-950
pubmed: 32010572
Genes Dev. 2018 Jul 1;32(13-14):915-928
pubmed: 29945888
Oncol Rev. 2012 Apr 02;6(1):e4
pubmed: 25992206
J Thorac Oncol. 2020 Dec;15(12):1823-1835
pubmed: 33011388
Sci Signal. 2019 Feb 05;12(567):
pubmed: 30723171
Jpn J Clin Oncol. 2018 Jul 1;48(7):603-608
pubmed: 29762727
Cell Cycle. 2011 Aug 15;10(16):2806-15
pubmed: 21822053
J Thorac Oncol. 2020 Apr;15(4):618-627
pubmed: 31870883
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15030-5
pubmed: 22927417
Clin Lung Cancer. 2016 Sep;17(5):325-333
pubmed: 27397481
Clin Cancer Res. 2019 Dec 1;25(23):6958-6966
pubmed: 31506387
Nature. 2010 Jan 14;463(7278):184-90
pubmed: 20016488
Nat Rev Clin Oncol. 2020 May;17(5):300-312
pubmed: 32055013
Nat Rev Cancer. 2017 Dec;17(12):725-737
pubmed: 29077690
J Exp Med. 1985 May 1;161(5):1135-51
pubmed: 2580935
Mol Oncol. 2020 Sep;14(9):1947-1965
pubmed: 32506804
Cancers (Basel). 2019 Oct 15;11(10):
pubmed: 31619019
Nature. 2017 May 18;545(7654):360-364
pubmed: 28489825
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
Lancet Oncol. 2020 May;21(5):645-654
pubmed: 32224306
Cancer Cell. 2017 Feb 13;31(2):286-299
pubmed: 28196596
Oncotarget. 2017 Apr 25;8(17):28575-28587
pubmed: 28212573
Transl Lung Cancer Res. 2018 Feb;7(1):4-20
pubmed: 29535909
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
Nat Rev Clin Oncol. 2017 Sep;14(9):549-561
pubmed: 28534531
Cancer Chemother Rep 3. 1973 Mar;4(2):63-7
pubmed: 4580861
J Thorac Dis. 2013 Oct;5 Suppl 5:S565-78
pubmed: 24163749
Pharmacology. 2020 Jul 28;:1-14
pubmed: 32721966
Clin Cancer Res. 2019 Aug 15;25(16):5107-5121
pubmed: 31164374
J Thorac Oncol. 2014 Mar;9(3):410-3
pubmed: 24518092
J Natl Cancer Inst. 2013 Jul 17;105(14):1059-65
pubmed: 23739064
Cancer Cell. 2020 Jul 13;38(1):17-20
pubmed: 32663464
Cell Tissue Res. 2015 Jan;359(1):99-109
pubmed: 25092546
Oncotarget. 2017 Aug 28;8(43):73745-73756
pubmed: 29088741
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Expert Opin Ther Targets. 2020 Feb;24(2):101-114
pubmed: 32003251
Transl Lung Cancer Res. 2018 Feb;7(1):21-31
pubmed: 29535910
J Immunother Cancer. 2019 Aug 5;7(1):205
pubmed: 31383005
J Clin Oncol. 2016 Nov 1;34(31):3740-3748
pubmed: 27458307
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):13087-13092
pubmed: 30514821
Med Res Rev. 2016 Nov;36(6):1036-1079
pubmed: 27406026
Am J Med. 1969 Apr;46(4):516-25
pubmed: 5791000
J Thorac Oncol. 2019 Nov;14(11):1878-1880
pubmed: 31668313
Oncologist. 2019 Nov;24(11):e1172-e1179
pubmed: 31068386
Lancet Oncol. 2015 Apr;16(4):395-405
pubmed: 25728526
Lung Cancer. 1999 Feb;23(2):159-68
pubmed: 10217620
J Pathol. 1999 Jan;187(2):191-9
pubmed: 10365094
J Thorac Cardiovasc Surg. 2011 Sep;142(3):538-46
pubmed: 21684554
Cancer Res. 1985 Jun;45(6):2913-23
pubmed: 2985257
J Thorac Oncol. 2019 Feb;14(2):237-244
pubmed: 30316010
Open Biol. 2017 Sep;7(9):
pubmed: 28878044
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
J Thorac Dis. 2017 Dec;9(12):4884-4888
pubmed: 29312683
Ann Oncol. 2020 Feb;31(2):310-317
pubmed: 31959349
Am J Med Sci. 2010 Jan;339(1):68-76
pubmed: 19996730
Oncotarget. 2016 Jan 19;7(3):3084-97
pubmed: 26625211